Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 221

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Glioma-Associated Cancer-Initiating Cells Induce Immunosuppression

Open access
Wei, Jun, Barr, Jason, Kong, Ling-Yuan, Wang, Yongtao, Wu, Adam, Sharma, Amit K., Gumin, Joy, Henry, Verlene, Colman, Howard, Sawaya, Raymond, Lang, Frederick F., Heimberger, Amy B.·2010·Clinical Cancer Research

Abstract

Purpose: Glioblastoma multiforme is a lethal cancer that responds poorly to therapy. Glioblastoma multiforme cancer-initiating cells have been shown to mediate resistance to both chemotherapy and radiation; however, it is unknown to what extent these cells contribute to the profound immunosuppression in glioblastoma multiforme patients and if strategies that alter their differentiation state can reduce this immunosuppression. Experimental Design: We isolated a subpopulation of cells from glioblastoma multiforme that possessed the capacity for self-renewal, formed neurospheres in vitro, were capable of pluripotent differentiation, and could initiate tumors in vivo. The immune phenotype of these cells was characterized including the elaboration of immunosuppressive cytokines and chemokines by ELISA. Functional immunosuppressive properties were characterized based on the inhibition of T-cell proliferation and effector responses, triggering of T-cell apoptosis, and induction of FoxP3+ regulatory T cells. On altering their differentiation state, the immunosuppressive phenotype and functional assays were reevaluated. Results: We found that the cancer-initiating cells markedly inhibited T-cell proliferation and activation, induced regulatory T cells, and triggered T-cell apoptosis that was mediated by B7-H1 and soluble Galectin-3. These immunosuppressive properties were diminished on altering the differentiation of the cancer-initiating cells. Conclusion: Cancer-initiating cells contribute to tumor evasion of the immunosurveillance and approaches that alter the differentiation state may have immunotherapeutic potential. Clin Cancer Res; 16(2); 461–73

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-09-1983This paper is marked retracted.

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 221

Metadata

Authors
Wei, J., Barr, J., Kong, L.-Y., Wang, Y., Wu, A., Sharma, A. K., Gumin, J., Henry, V., Colman, H., Sawaya, R., Lang, F. F., & Heimberger, A. B.
Venue
Clinical Cancer Research
Published
2010-01-14
Volume
16
Issue
2
Pages
461-473
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2010884432
Cited by
221
References
3
FWCI
12.18
Type
journal article
Language
en
Status
Retracted
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glioma-Associated Cancer-Initiating Cells Induce Immunosuppression. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-09-1983
The paper
Wei, J., Barr, J., Kong, L.-Y., Wang, Y., Wu, A., Sharma, A. K., Gumin, J., Henry, V., Colman, H., Sawaya, R., Lang, F. F., & Heimberger, A. B. (2010). Glioma-Associated Cancer-Initiating Cells Induce Immunosuppression. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-09-1983

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.